PA
PRQR icon

Parallel Advisors’s ProQR Therapeutics PRQR Stock Holding History

Parallel Advisors’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-770
Closed -$6K – 3211
2021
Q4 		$6K Buy
770
+752
+4,178% +$5.73K ﹤0.01% 2339
2021
Q3 		$0 Sell
18
-173
-91% -$1.13K ﹤0.01% 3232
2021
Q2 		$1K Buy
+191
New +$1.23K ﹤0.01% 2805
2020
Q4 		– Sell
-308
Closed -$1K – 2689
2020
Q3 		$1K Buy
+308
New +$1.61K ﹤0.01% 2478
2020
Q2 		– Sell
-424
Closed -$2K – 2659
2020
Q1 		$2K Buy
424
+199
+88% +$1.53K ﹤0.01% 2158
2019
Q4 		$2K Buy
+225
New +$1.75K ﹤0.01% 2234
2019
Q3 		– Sell
-336
Closed -$3K – 2471
2019
Q2 		$3K Buy
+336
New +$3.96K ﹤0.01% 2004

Other funds holding PRQR

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Parallel Advisors's PRQR Position: Q1 2022 in Review

Parallel Advisors sold out of ProQR Therapeutics (PRQR) in Q1 2022, closing a stake of 770 shares — an estimated $6K sold.

Parallel Advisors first reported a position in PRQR in Q2 2019 and held it in 7 quarters. The position peaked at $6K in Q4 2021. 58 funds tracked by Wall St. Rank hold PRQR as of Q1 2022.

  • Parallel Advisors reported no remaining ProQR Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Parallel Advisors sold 770 ProQR Therapeutics shares in Q1 2022, an estimated $6K.
  • Parallel Advisors first reported a position in ProQR Therapeutics in Q2 2019 and held it in 7 quarters.
  • Parallel Advisors's ProQR Therapeutics position peaked at $6K in Q4 2021.
  • 58 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2022.

Based on Parallel Advisors's 13F filing for Q1 2022, filed 28 Apr 2022.